High PSA levels may show body is fighting cancerBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7216.1025 (Published 16 October 1999) Cite this as: BMJ 1999;319:1025
- Debbie Josefson
- San Francisco
New research shows that prostate specific antigen (PSA), a commonly used serum marker of prostate cancer, inhibits the formation of new blood vessels and consequently slows the progression of the disease (Journal of the National Cancer Institute 1999;91:1635-40).
The finding may explain the characteristic indolent nature of most prostate cancers and calls into question experimental vaccine strategies that involve vaccinating people against the antigen.
Angiogenesis, or the formation of new blood vessels, is essential for tumour growth and metastasis, and many cancers are thought to produce angiogenic substances to promote their own growth. Accordingly, several research groups and biotechnology firms are hunting for angiogenesis inhibitors to use as antineoplastic agents.
Although used as both a screening test for …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.